



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 MADRID

Granada, 21 October 2015

RELEVANT FACT OF NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby puts in knowledge the following information.

Neol Bio, subsidiary of Neuron Bio and Antibióticos de León have reached a framework agreement for different areas that encompasses the scale-up and industrial production, the implementation of common projects, research and co-development programs as well as commercial activities of mutual interest and also the joint exploitation of certain products.

Noteworthy among the industrial projects to exploit is the production of Omega 3 docosahexaenoic acid (DHA) rich oil through the cultivation of microalgae. Sufficient intake of DHA is especially important for strengthening the neuronal development and preventing neurodegenerative disorders.

Antibióticos de León is a pioneer in the world for the production of pharmaceutical active ingredients. The factory, which has a fermentation capacity of over 3,000 cubic meters, is the major biotechnological production plant in south Europe. It has specialized equipment and skilled staff for the industrialization of biotechnology processes of nutraceuticals, biocatalysts, biopolymers, biofuels and other bioproducts.

Press release is enclosed.

We remain at your disposal for any clarification you consider appropriate.
Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors

Press release

Neol Bio and Antibióticos de León agree to join commercialization and production of high-value oils

- **The initiative will accelerate the implementation of fermentation processes in the factory of León.**

Granada, 21 October 2015-. Neol Bio, subsidiary of Neuron Bio (NEU.MAB) and the company Antibióticos de León have reached a framework agreement for different areas that encompasses the scale-up and industrial production, the implementation of common projects, research and co-development programs as well as commercial activities of mutual interest and also the joint exploitation of certain products.

Noteworthy among the industrial projects to exploit is the production of Omega 3 docosahexaenoic acid (DHA) rich oil through the cultivation of microalgae. Sufficient intake of DHA is especially important for strengthening the neuronal development and preventing neurodegenerative disorders.

Neol Bio develops its activities in the field of industrial biotechnology, a key technological sector for the Bioeconomy development. Industrial biotechnology has been identified as one of the essential technologies from the present for the future.

In order to its development in this market, Neol Bio has a 33 people staff (8 Ph.D.) from which 28 are completely dedicated to R&D projects. Moreover, it has a proprietary microbial collection of over 9,000 microorganisms, cutting-edge equipment in the field of industrial biotechnology including robotic technologies for selection of industrial microorganisms and a fermentation & downstream pilot plant to demonstrate the developed processes.



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Meanwhile, Antibióticos de León is a pioneer in the world for the production of pharmaceutical active ingredients. The factory, which has a fermentation capacity of over 3,000 cubic meters, is the major biotechnological production plant in south Europe. It has specialized equipment and skilled staff for the industrialization of biotechnology processes of nutraceuticals, biocatalysts, biopolymers, biofuels and other bioproducts.

At the end of year 2014 Antibióticos de León entered upon a new phase after the acquisition of its productive unity by the fund Black Toro Capital (BTC), thus employing over 190 people currently.

Javier Velasco, CEO of Neol Bio said, *“This agreement enables Neol to access to technical and industrial capacities of a big company like Antibióticos de León, which would accelerate the production process of our DHA rich oil at very competitive production costs, due to the high productivity of the process. So, we achieve appropriate performance quickly in order to make this bioprocess economically profitable and not depend upon scarce resources such as the fish oil.”*

The CEO of Antibióticos de León Juan Molins stated, *“This agreement with Neol is one more step towards making of Antibióticos de León a technology cluster regarding our fermentation capacity. Our facilities and our staff have the best conditions to develop high-performance and high-valued projects.”*

For more info, please contact with

Malena Valdivieso
mvaldivieso@neuronbio.com
Tel.: +34 958 750 598
www.neuronbio.com



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Note for editors

About Neol Bio

Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

Due to the use of advanced molecular biology techniques, bioprocess engineering and industrial microbiology, Neol achieves economically viable bioprocesses, thus reducing the use of chemical contaminants and assessing agricultural and industrial waste.

Neol has facilities, laboratories and cutting-edge equipment in the biotechnology field as well as an own pilot plant for demonstration of the processes it develops.

Neol has a team of over 30 high qualified researchers, such as microbiologists, molecular biologists, experts in analytical chemistry and bioprocesses engineers with renowned prestige in the sector, who participate actively in numerous scientific projects.

Its headquarters and main facilities are located in the Granada Bio Science & Technology Park.